Understanding the microbiome may hold the key to personalized therapies

Advances in high-throughput experimentation and machine learning are helping researchers map how gut microbes influence drug response and health outcomes. Understanding the gut microbiome could improve drug design, patient matching, and therapeutic outcomes.

Over the past decade, scientific understanding of the human microbiome has expanded far beyond the idea of a handful of commensal microbes. Researchers now recognize the microbiome as a vast and dynamic ecosystem that plays a central role in metabolism, immunity, and disease.

However, understanding the microbiome is particularly challenging due to its scale and variability. The human gut microbiome encodes an estimated 150 times more genes than the human genome, and this second genome can differ substantially between individuals. These differences have been linked to a wide range of conditions, from inflammatory and metabolic diseases to neurological and cardiovascular disorders, and are increasingly implicated in why patients respond differently to the same therapy.

Despite this growing body of evidence, the microbiome remains largely absent from routine drug development and clinical decision-making. Much of the research to date has been correlative, relying on sequencing-based surveys that describe which microbes are present but not what they are doing. Data are often low-throughput, inconsistent across laboratories, or derived from animal models that do not fully reflect human biology. As a result, translating microbiome insights into predictive, clinically actionable tools has proven difficult.

Against this backdrop, there is growing interest in making human microbiology more computable by pairing functional wet-lab data with machine learning. Founded in 2025 and based in Massachusetts, Outpost Bio is one of a small number of startups taking this approach, developing integrated experimental and computational systems to model how microbial interactions influence human biology and drug response.